Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eton Pharmaceuticals, Inc. (ETON)
|
Add to portfolio |
|
|
|
| Price: |
$4.48
| | Metrics |
| OS: |
25.7
|
M
| |
-1
|
% ROE
|
| Market cap: |
$115
|
M
| |
|
|
|
Net cash:
|
$15.5
|
M
| |
$0.60
|
per share
|
|
EV:
|
$99.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$362.0
|
k
| |
274.7
|
x EV/EBITDA
|
|
EBIT
|
($484.0)
|
k
| |
|
|
| EPS |
($104.12)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 21.3 | 21.8 | 0.0 | 1.0 | 0.0 |
| Revenue growth | -2.7% | 55879.5% | -95.9% | | |
| Cost of goods sold | 6.9 | 2.8 | 0.4 | 0.5 | 0.0 |
| Gross profit | 14.3 | 19.0 | -0.4 | 0.5 | 0.0 |
| Gross margin | 67.4% | 87.1% | -1017.9% | 52.8% | |
| Research and development | 4.0 | 6.2 | 14.1 | 11.6 | 5.6 |
| General and administrative | 18.6 | 14.3 | 12.6 | 7.6 | 4.7 |
| EBITA | -6.6 | -1.1 | -27.0 | -18.6 | -10.3 |
| EBITA margin | -31.3% | -5.1% | -69130.8% | -1937.0% | |
| Amortization of intangibles | 1.6 | 0.2 | 0.2 | 0.0 | |
| EBIT | -8.3 | -1.3 | -27.1 | -18.6 | -10.3 |
| EBIT margin | -38.9% | -6.0% | -69515.4% | -1939.6% | |
| Pre-tax income | -9.0 | -2.0 | -28.0 | -18.3 | -12.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -9.0 | -2.0 | -28.0 | -18.3 | -37.2 |
| Net margin | -42.4% | -9.0% | -71717.9% | -1910.3% | |
| |
| Diluted EPS | ($0.36) | ($0.08) | ($1.33) | ($1.03) | ($5.80) |
| Shares outstanding (diluted) | 25.1 | 25.2 | 21.0 | 17.8 | 6.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|